Email sent to the Gilead Development TeamAcquisition Agreement • September 16th, 2020 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
This is the 10th agreement announced this year, as we work to build and expand our Oncology portfolio. As we work on communication – within the Development organization and across Gilead – it is important to me that we address questions as they arise. I understand that across our group, the agreement has generated some conversation about what this means in the context of our commitment to our other TAs. I want to emphasize – as Dan and other LT members did at yesterday’s State of Gilead – that we remain deeply committed to Virology and Inflammation. In fact, it is because of our success in Virology that we have been able to support our growth in Oncology. Across each of our therapeutic areas, we have a common goal: to improve outcomes for people in areas of unmet medical need. The recent investments in oncology do not signal a withdrawal in Inflammation, but rather a diversification of our portfolio, which better secures our pursuit of success in all of our therapeutic areas. We cannot
